Counsel from Sullivan & Cromwell LLP, Teva and Eli Lilly & Company to Chair ACI's PIV this April

NEW YORK - March 18, 2024 - PRLog -- American Conference Institute (ACI) is pleased to announce that Andrei Iancu (Former Director of the USPTO) from Sullivan & Cromwell LLP, Brian Malkin from Teva, and Mira Mulvaney from Eli Lilly & Company, will be chairing the 20^th Anniversary Paragraph IV Disputes conference which celebrates the 40^th Anniversary of the Hatch-Waxman Act, taking place on April 25-26, 2024, in New York City.

Andrei Iancu comments, "As is the case every year, this year's Paragraph IV Dispute conference provides an unparalleled look at a critically important industry and the legal system that protects it. I am honored to co-chair the conference and very much look forward to in-depth discussions and analysis of the latest trends and developments, as we celebrate four decades of the Hatch-Waxman Act. The patent system has been at the core of the American economy since this country was founded, and it is now more important than ever to ensure a balanced system that maximizes the effectiveness of the entire industry for the good of patients and the public at large."

Brian Malkin notes that, "Between the 40^th anniversary of the Hatch-Waxman Act and the many recent developments we have seen in the Hatch-Waxman space, it is a thrilling time to be co-chairing the ACI PIV Disputes Conference. We have an amazing group of thought leaders weighing in on cutting edge topics and I look forward to hearing their different perspectives as we discuss how far we have come in the past 40 years and where we are headed in the next 40."

Mira Mulvaney adds, "I am honored to co-chair this year's ACI PIV Disputes Conference as we help celebrate the 40-year anniversary of the Hatch-Waxman Act and the significant contributions it has made to foster competition for both innovative/follow-on medicines and develop a vibrant and sustainable generic drug industry in a pro-competitive environment. This year we will present not only current developments for both in-house and outside counsel practitioners but also reflect upon where we were in 1984 when the Act first came online, whether the Act is still working, and how we can continue to build upon its success to continue the pipeline of new innovative and generic medicines."

Full information on the event, visit https://www.americanconference.com/paragraph-iv-disputes/

# # #

A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world.